1	Cross-ancestry genetic architecture and prediction for cholesterol traits		
2			
3	Md. Moksedul Momin ^{1,2,3,4*} , Xuan Zhou ^{1,2,4} , Elina Hyppönen ^{1,4,5} , Beben Benyamin ^{1,2,4} , and		
4	S. Hong Lee ^{1,2,4*}		
5			
6 7	¹ Australian Centre for Precision Health, University of South Australia, Adelaide, SA, 5000, Australia		
8 9	² UniSA Allied Health and Human Performance, University of South Australia, Adelaide, SA, 5000, Australia		
10 11 12	³ Department of Genetics and Animal Breeding, Faculty of Veterinary Medicine, Chattogram Veterinary and Animal Sciences University (CVASU), Khulshi, Chattogram, 4225, Bangladesh		
12 13 14	⁴ South Australian Health and Medical Research Institute (SAHMRI), University of South Australia, Adelaide, SA, 5000, Australia		
15 16	⁵ UniSA Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia		
17 18	Correspondance : <u>Cvasu.Momin@gmail.com</u> and <u>Hong.Lee@unisa.edu.au</u>		
19	Abstract		
20	While cholesterol is essential for human life, a high level of cholesterol is closely linked with the risk of cardiovascular diseases. Genome wide association studies ($GWASs$) have been		
22	successful to identify genetic variants associated with cholesterol, which have been conducted		
23 24	mostly in white European populations. Consequently, it remains mostly unknown how genetic effects on cholesterol vary across ancestries. Here, we estimate cross-ancestry genetic		
25 26	correlation to address questions on how genetic effects are shared across ancestries for cholesterol. We find significant genetic heterogeneity between ancestries for total- and L DL -		
27	cholesterol. Furthermore, we show that single nucleotide polymorphisms (SNPs), which have		

- polygenic prediction. The list of concordant SNPs for cholesterol is available in GWAS 33
 - Catalog (https://www.ebi.ac.uk/gwas/; details are in web resources section). These findings 34 35 have relevance for the understanding of shared genetic architecture across ancestries, 36 contributing to the development of clinical strategies for polygenic prediction of cholesterol in

concordant effects across ancestries for cholesterol, are more frequently found in the regulatory

region, compared to the other genomic regions. Indeed, the positive genetic covariance between

ancestries is mostly driven by the effects of the concordant SNPs, whereas the genetic

heterogeneity is attributed to the discordant SNPs. We also show that the predictive ability of

the concordant SNPs is significantly higher than the discordant SNPs in the cross-ancestry

- 37 cross-ancestral settings
- 38

28

29

30

31

32

39 Introduction

40 Cholesterol is a type of lipid that is essential for human life, forming an essential structural

- component of the cell membrane¹⁻³. While cholesterol is necessary for human body to function, 41
- 42 too much cholesterol can harm the body. High cholesterol is linked with a high risk of
- 43 cardiovascular diseases (CVDs), such as coronary heart disease, stroke, and peripheral vascular
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. disease, which are the leading cause of death worldwide⁴, accounting for 32% of all deaths in 44

2019⁵. Specifically, elevated low-density lipoprotein (LDL) and decreased high-density
lipoprotein (HDL) cholesterols are associated with increased CVD risk⁶⁻⁹. These cholesterol
traits are heritable and known to be polygenic^{6, 10, 11}. Reported heritability estimates for total-,
LDL- and HDL-cholesterols are typically in the range of 20 to 60%¹².

49

50 Over the last two decades, genome-wide association studies (GWASs) have successfully 51 identified several genome-wide significant single nucleotide polymorphisms (SNPs) associated with cholesterol traits^{4, 13-15}. While these findings have provided important insights into the 52 genetics of cholesterol, most GWAS for cholesterol to date have been conducted in populations 53 of white European ancestry¹⁶⁻¹⁸. Although the number of GWASs representing non-European 54 populations are gradually increasing, they still remain greatly underrepresented in the efforts 55 of gene discovery^{16, 19}. Consequently, how genetic effects on cholesterol vary across ancestries 56 remain mostly unknown^{20, 21}. It is also not clear to what extent the associated genetic variants 57 58 discovered in European populations are relevant for other ancestries (e.g., South Asian and African ancestries), and if the polygenic risk prediction of cholesterol can be applied across 59 ancestries²²⁻²⁵. 60

61

62 The genetic effects on most complex traits are likely to vary at least to some extent across different ancestry groups^{26, 27}. Cross-ancestry genetic correlation analyses can dissect the 63 shared genetic architecture between diverse ancestries, also allowing to leverage power from 64 diverse sources of information²⁸. While common causal variants for cholesterol are likely to be 65 66 shared across ancestries, their per-allele effect sizes may depend on allele frequencies that can differ across ancestries due to different evolutionary force such as selection and genetic drift²⁹. 67 Moreover, each ancestry has a unique genetic background that may affect the magnitude and 68 direction of per-allele effect sizes for complex traits such as cholesterol³⁰. It has been reported 69 70 that the relationship between allele frequency and per-allele effect size varies across different 71 ancestries, which should be properly accounted for. otherwise, the estimation of cross-ancestry 72 genetic correlation can be biased $^{31, 32}$.

73

Cross-ancestry genetic prediction can reduce the potential health disparity for non-European populations that are still underrepresented in public genomic databases including GWAS and polygenic risk scores (PRS)³³. It is crucial to understand the source of genetic heterogeneity across ancestries in the genetic prediction. In general, it is not likely that SNP effects estimated from a single ancestry group are always applicable to other ancestries, which has a practical

relevance. For example, several studies have reported that the predictive ability of complex traits including cholesterol was poor for Africans, East-Asians, South-Asians and Latinos, when using SNP effects estimated in Europeans^{19, 34, 35}. To obtain more reliable cross-ancestry genetic prediction, it may be important to restrict to functionally homogenous genes or common causal variants across ancestries^{28, 36}. We hypothesize that SNPs in strong linkage disequilibrium (LD) with the functionally homogenous genes have concordant effects, i.e., the same direction of SNP effects, across ancestries.

86

87 In this study, we estimate cross-ancestry genetic correlation to address the question about how genetic effects are shared across ancestries for cholesterol traits, accounting for the relationship 88 between allele frequency and per-allele effect size³¹. In the estimation of cross-ancestry genetic 89 90 correlation, we also investigate the role of concordant SNPs that are derived from comparing 91 SNP effects between two independent GWAS datasets of UK Biobank and Biobank Japan (BBJ). We evaluate the transferability of genetic prediction across different ancestry groups 92 93 and suggest a list of SNPs that are suitable for the use in polygenic risk prediction in cross-94 ancestry analyses.

- 95
- 96

97 **Results**

98 **Overview of methods**

99 The total numbers of individuals and SNPs for each ancestry after stringent quality control (QC) 100 (Methods) are shown in **Supplementary Table 1**. From the quality-controlled data of 288,837 101 white British people, we randomly selected 30,000 individuals to be used in the analyses of 102 cross-ancestry genetic correlations. The remaining 258,792 individuals were used as the 103 discovery dataset in the cross-ancestry genetic risk prediction and in the classification of 104 concordant SNPs (referred to as UKBB discovery). In the cross-ancestry genetic analysis of 105 total-, HDL- and LDL-cholesterol, four ancestry groups were included, i.e. the 30,000 white British ancestry group, 26,457 other European, 6,199 south Asian and 6,179 African ancestry 106 107 groups (Supplementary Table 1). We accounted for the relationship between per-allele effect size and allele frequency^{31, 37} by using trait-specific and ancestry-specific α that was explicitly 108 estimated for each trait and each ancestry, using Akaike information criterion (AIC)^{31, 32}. We 109 used the common SNPs for each pair of ancestries to estimate the cross-ancestry genetic 110 correlation, using the bivariate GREML approach³⁸, accounting for the relationship between 111 allele frequency and per-allele effect size³¹. We further investigated if the set of concordant 112

113 SNPs, which were derived by comparing UKBB and Biobank Japan discovery GWAS 114 summary statistics for cholesterol, is enriched in the regulatory region, compared to the other 115 genomic regions. The list of concordant SNPs for total-, HDL- and LDL-cholesterol are now 116 available in GWAS catalogue. Cross-ancestry genetic covariance was partitioned, based on the 117 sets of concordant and discordant SNPs, to see how the genetic heterogeneity is attributed to 118 those SNP sets (see **Supplementary Table 4**). Finally, cross-ancestry polygenic prediction was 119 performed based on the sets of concordant and discordant SNPs.

120

121 Determining trait-specific and ancestry-specific scale factor (α) for each ancestry

122 The scale factor (α) can account for the relationship between allele frequency and per-allele 123 effect size, that is, per-allele effect sizes vary, proportional to $[p(1-p)]^{\alpha}$, where p is the allele frequency^{32, 39, 40}. It is also reported that the scale factor is not uniformly distributed across 124 ancestries, and there may be an optimal α value for each specific ancestry group³¹. Following 125 the previous approach^{31, 32}, we investigated various α values ranging between -1 and 0.5 to 126 127 determine the ancestry specific α value of each ancestry group for total-, LDL- and HDL-128 cholesterol. To determine optimal α , we compared the Akaike Information Criteria (AIC) 129 values across different heritability models with various α values for each trait and each ancestry 130 (Figure 1). Detailed values of log-likelihood and AIC are provided in Supplementary Table 131 6-9. As expected, optimal α values are not uniformly distributed across traits and across 132 ancestries (Figure 1). These identified α values are subsequently used in the estimation of cross-133 ancestry genetic correlations to dissect the shared genetic architecture and investigate genetic 134 heterogeneity across ancestries for the cholesterol related traits.



135 136 Figure 1: Determining the optimal ancestry-specific scaling factors (α) for each trait. The α value reflects the relationship between allele frequency and per-allele effect size and can vary 137 138 across ancestries and traits. \triangle AIC values are plotted against scaling factors, α , for each ancestry 139 group. The lowest AIC (i.e., $\Delta AIC=0$) indicates the best model. The sample sizes are 30,000, 26,457, 6,199, and 6,179 for white British, other European, South Asian, and African ancestry 140 groups, respectively. TC: total-cholesterol, HDL: high-density lipoprotein cholesterol, LDL: 141 142 low-density lipoprotein cholesterol.

143

144 Heritability (h^2) estimates across ancestries

145 The estimated SNP-based heritabilities of total-, LDL- and HDL-cholesterol are presented in 146 Figure 1. The estimates are significantly different particularly between European and African

- ancestries. For total-cholesterol, there is a significant difference in SNP-based heritability 147
- 148 estimates between African vs. European (p-value=4.26e-03), and African vs white British (p-
- value=1.14e-03). Similarly, the estimate of LDL-cholesterol is significantly lower in white 149
- British (*p*-value= 1.11e-03) and other European (*p*-value= 5.19e-03) than African ancestry, 150
- which agrees with the previous findings based on twin studies⁴¹. We also observed significant 151

- 152 heterogeneity of SNP-based heritability for the HDL-cholesterol between South Asian and
- 153 other Europeans, between South Asian and white British.
- 154



155

156 Figure 2: Estimated SNP-based heritability across ancestries for cholesterol traits. The 157 main bars indicate SNP-based heritability estimates, and the error bars indicate 95% confidence 158 intervals. TC= Total-cholesterol, HDL= high-density lipoprotein cholesterol, LDL= low-159 density lipoprotein cholesterol.

160

161 Estimated cross-ancestry genetic correlations

The estimated cross-ancestry genetic correlations (r_g) for cholesterol traits are presented in 162 Figure 3. For total-cholesterol, we observed a genetic heterogeneity between South Asian vs. 163 white British ($r_g = 0.399$; SE= 0.143; *p*-value= 2.65e-05), South Asian vs. other European ($r_g = 0.399$) 164 0.353; SE=0.133; p-value= 1.14e-06) and South Asian vs. African ancestry ($r_q = 0.188$; 165 166 SE=0.197; p-value= 3.76e-05). There is also a genetic heterogeneity between African vs. white British ($r_q = 0.473$; SE=0.127; *p*-value= 3.33e-05) and African vs. other European ancestry ($r_q = 0.473$; SE=0.127; *p*-value= 3.33e-05) and African vs. other European ancestry ($r_q = 0.473$; SE=0.127; *p*-value= 3.33e-05) and African vs. other European ancestry ($r_q = 0.473$; SE=0.127; *p*-value= 3.33e-05) and African vs. other European ancestry ($r_q = 0.473$; SE=0.127; *p*-value= 3.33e-05) and African vs. other European ancestry ($r_q = 0.473$; SE=0.127; *p*-value= 3.33e-05) and African vs. other European ancestry ($r_q = 0.473$; SE=0.127; *p*-value= 3.33e-05) and African vs. other European ancestry ($r_q = 0.473$; SE=0.127; *p*-value= 3.33e-05) and African vs. other European ancestry ($r_q = 0.473$; SE=0.127; *p*-value= 3.33e-05) and African vs. other European ancestry ($r_q = 0.473$; SE=0.127; *p*-value= 3.33e-05) and African vs. other European ancestry ($r_q = 0.473$; SE=0.127; *p*-value= 3.33e-05) and African vs. other European ancestry ($r_q = 0.473$; SE=0.127; *p*-value= 3.33e-05) and African vs. other European ancestry ($r_q = 0.473$; SE=0.127; *p*-value= 3.33e-05) and African vs. other European ancestry ($r_q = 0.473$; SE=0.127; *p*-value= 3.33e-05) and African vs. other European ancestry ($r_q = 0.473$; SE=0.127; *p*-value= 3.33e-05) and African vs. other European ancestry ($r_q = 0.473$; SE=0.127; *p*-value= 3.33e-05) and African vs. other European ancestry ($r_q = 0.473$; SE=0.127; *p*-value= 3.33e-05) and African vs. other European ancestry ($r_q = 0.473$; SE=0.127; *p*-value= 3.33e-05) and African vs. other European ancestry ($r_q = 0.473$; SE=0.127; *p*-value= 3.33e-05) and African vs. other European ancestry ($r_q = 0.473$; SE=0.127; *p*-value= 3.33e-05) and African vs. other European ancestry ($r_q = 0.473$; SE=0.127; *p*-value= 3.33e-05) and African vs. other European ancestry ($r_q = 0.473$; SE=0.127; SE=0.127 167 0.315; SE=0.122; p-value=1.96e-08). In contrast, white British and other European are 168 genetically homogenous ($r_q = 0.954$; SE=0.087; p-value= 5.96e-01) (Figure 3 and 169 170 **Supplementary Table 10**). For LDL-cholesterol, results are similar to total-cholesterol. There is a significant genetic heterogeneity between South Asian vs. white British ($r_q = 0.296$; 171 SE=0.155; p-value=5.57e-06), South Asian vs. other European ($r_g = 0.177$; SE=0.138; p-172 value=2.46e-09), South Asian vs. African ($r_g = 0.110$; SE=0.190; p-value=2.81e-06), and 173 174 African vs. other European ancestry ($r_q = 0.409$; SE=0.147; *p*-value=2.81e-06) (Figure 3 and Supplementary Table 11). As expected, the cross-ancestry genetic correlation between other 175 European and white British was close to 1 (r_q = 1.084; SE=0.128; *p*-value=5.12e-01). We did 176 not observe genetic heterogeneity among the pairs of ancestry groups for HDL-cholesterol 177 178 (Figure 3 and Supplementary Table 12). 179



180

181 Figure 3: Estimated cross-ancestry genetic correlations. The main bars indicate estimated cross-ancestry genetic correlations, and the error bars indicate 95% confidence intervals of the 182 estimates. WB = White British, OE = Other European, SAS = South Asian, AFR = African. 183 184

185 Genomic partitioning of cross-ancestry genetic covariance using concordant and 186 discordant SNPs between two diverse ancestries

Some genes are functionally homogeneous across ancestries while the other genes may not be³⁶, 187 ^{42, 43}. It can be hypothesised that the functionally homogenous genes are enriched in the 188 189 regulatory regions, and they contribute more to phenotypic variation within and between 190 ancestries, compared to the other genes. We obtained a set of concordant SNPs (a proxy of 191 functionally homogenous genes) for total-, HDL-, and LDL-cholesterols, by comparing the 192 direction of SNP effects between two diverse ancestries, using the GWAS summary statistics 193 of UK Biobank and Biobank Japan. For the UK Biobank GWAS, we used 258,792 white 194 British individuals who are not overlapping with anyone in the 4 ancestry groups used in our study (white British, other European, South Asian, and African). For the Biobank Japan, we 195 196 used GWAS summary statistics that are publicly available. In this concordance/discordance analysis, we considered the same HapMap3 SNPs used in the genetic correlation analyses 197

above. The numbers of concordant and discordant SNPs for each pair of ancestries arepresented in Supplementary Table 4.

200

201 First, we quantified if the concordance SNPs are more frequently found in the regulatory or 202 genic region, compared to the other genomic regions for total-cholesterol. Figure 4 shows that 203 the number of concordant SNPs in the regulatory region is significantly higher than the non-204 regulatory region (OR= 1.09, *p*-value=2.2e-26 for *p*-value \leq 1; OR= 1.21, *p*-value=9.2e-16 for 205 *p*-value ≤ 0.05 ; OR= 1.18, *p*-value=1.6e-06 for *p*-value ≤ 0.01). When selecting SNPs with a 206 genome-wide association (GWA) *p*-value > 0.05 or 0.01, the odds ratio increases (**Figure 4**). Similarly, the number of concordant SNPs in the genic region is significantly higher than the 207 208 non-genic region (OR= 1.03, p-value=1.8e-16 for p-value \leq 1; OR= 1.17, p-value=1.6e-32 for 209 p-value ≤ 0.05 ; OR= 1.18, p-value=1.8e-06 for p-value ≤ 0.01) (Figure 4). Similar results were 210 observed when using the HDL- and LDL-cholesterol traits (Supplementary Figure 1 and 2).



211

Figure 4: A forest plot with odds ratios indicating that concordant SNPs are more frequently found in the regulatory or genic region. This analysis is for total-cholesterol phenotypes. Error bar represents 95% confidence intervals. The *p*-value of odds ratio indicates that the odds ratio is significantly different from 1. For regulatory or genic region, a genomewide association (GWA) *p*-value threshold ≤ 1 , 0.05 or 0.01 was used to select a set of concordant and discordant SNPs using UK Biobank GWAS summary statistics for totalcholesterol.

219

Subsequently, we partitioned genetic covariance components attributed to the two sets of genomic regions (concordant vs. discordant SNPs). We estimated two genomic relationship matrixes (GRM), using the sets of concordant and discordant SNPs, which were simultaneously

223 fitted in a bivariate multiple random-effects model. When considering the set of concordant 224 SNPs, the estimated genetic covariances between other European (OE) vs. south Asian (SAS), 225 white British (WB) vs. African (AFR) and WB vs. OE were significantly higher than the 226 expectation (the proportion of the concordant SNPs) for total-cholesterol (Figure 5). On the 227 other hand, the estimated genetic covariances for these pairs of ancestries were significantly 228 lower than the expectation when using discordant SNPs (Figure 5). For HDL-cholesterol 229 (Supplementary Figure 3) and LDL-cholesterol (Supplementary Figure 4), a similar result 230 was observed that the estimated genetic covariances between OE vs. SAS, WB vs. OE and WB 231 vs. SAS were significantly deviated from the expectation. When using SNPs with genomewide association p-values < 0.05 or 0.01 (Supplementary Table 4), the estimated genetic 232 233 covariances due to concordant and discordant SNPs were more significantly deviated from the 234 expectation in general (Figure 5, Supplementary Figure 3 and 4). It is also noted that the estimated genetic covariances for the set of discordant SNPs were not higher than zero (Figure 235 236 5), implying that the genetic heterogeneity of cholesterol traits across ancestry might be mostly 237 due to the set of discordant SNPs. This also shows that the set of concordant SNPs may be 238 useful in cross-ancestry polygenic risk predictions. The results are similar when genome-wide 239 association p-values from BBJ are used (Supplementary Figure 5).

240 241



242



245 effects between two independent GWAS datasets of UK Biobank and BBJ. In this concordant 246 or discordant analysis, a set of SNPs with genome-wide association (GWA) *p*-values < 1, 0.05 247 or 0.01 was used, where the GWA p-values were from UK Biobank GWAS for total-248 cholesterol. The main bars represent estimated cross-ancestry genetic covariance using the set 249 of genome-wide SNPs, and the error bars indicate 95% confidence intervals. The horizontal 250 dashed line indicates the expected genetic covariance, assuming all SNPs contribute equally to 251 the genetic covariance, i.e., the expected genetic covariance = the estimated total genetic 252 covariance \times the proportion of number of concordant SNPs, where the estimated total genetic 253 covariance is based on all the SNPs including both concordant and discordant SNPs. The value 254 with each bar indicates a *p*-value testing the null hypothesis that the estimated genetic 255 covariance is not significantly different from the expectation. WB = White British, OE = Other 256 European, SAS = South Asian, AFR = African.

257

258 We further investigated the impact of concordant SNPs in a cross-ancestry polygenic risk 259 prediction. We used the UKBB discovery dataset, which is independent from the four target 260 datasets including white British, other European, South Asian, and African ancestries, to 261 estimate SNP effects and obtain GWAS summary statistics for cholesterol traits. Using the 262 GWAS summary statistics, we constructed polygenic risk scores for the individuals in the target datasets. The predictive ability (R^2) of polygenic risk scores for total-cholesterol is 263 264 significantly higher when using the set of concordant SNPs than when using the set of 265 discordant SNPs for both within- and cross-ancestry predictions (Figure 6, Supplementary 266 Figure 4) (p-values for the difference between concordant and discordant PRS SNPs are 3.8e-267 33, 2.2e-25, 1.3e-04 and 5.3e-04 for white British, other European, South Asian and African, respectively). Although not significant, R^2 is slightly higher when using the set of concordant 268 SNPs, compared to when using the total set of SNPs (Figure 6), suggesting that including 269 270 discordant SNPs may have adverse effects on the cross-ancestry risk predictions. When 271 accounting for the proportion of concordant SNPs, a similar result was observed in that 272 concordant SNPs performed better that discordant SNPs in within- and cross-ancestry risk 273 predictions (Supplementary Figure 5). A similar finding was observed when using BBJ 274 discovery GWAS summary statistics, i.e., the cross-ancestry prediction accuracy of the 275 concordant SNPs significantly higher than the discordant SNPs (Supplementary Figure 4). 276 Interestingly, the concordant SNPs performs notably better than the total set of SNPs when 277 predicting white British, other European and south Asian ancestries (Supplementary Figure 278 4). Results are invariant when considering LDL- and HDL-cholesterol (Supplementary Figures 279 6-7).

280

281 For HDL cholesterol, it is notable that the accuracy of cross-ancestry prediction can be higher 282 than within-ancestry prediction (e.g., South Asian vs. White British in Supplementary Figure 283 6). We further confirmed this result with a clump-and-threshold (C + T) based PRS method (PRSice)⁴⁴ and compared the significance of difference (Supplementary Figure 8). It shows 284 285 that PGS generated from White British GWAS provides a significantly higher predictive 286 accuracy for South Asian (p-value = 6.67e-16) and African ancestry groups (p-value = 7.35e-16) 287 04), compared to White British. This may have an important implication in genomic medicine 288 for underrepresented non-European populations.

- 289
- 290



291

Figure 6: The predictive ability (R^2) of polygenic risk scores for total-cholesterol when

- using the set of concordant, discordant, or total SNPs for cross-ancestry risk predictions.
 UK Biobank GWAS was used as the discovery dataset (n= 258,792), while target datasets were
- other European (n=26,457), south Asian (n=6,199) and African ancestry (n=6,179).

296 Left panels: The main bars represent R^2 values and error bars correspond to 95% confidence 297 interval.

298 **Right panels:** Dot points represent the differences between R^2 values, error bars correspond

- to 95% confidence intervals of the differences, and *p*-values indicate that the differences of R^2 are significantly different from zero (null hypothesis). P-values was estimated using an Rpackage (r2redux)⁴⁵ based on Wald's test statistics.
- package (r2redux)¹⁰ based on wald's test statistics.
- 302

303 Discussion

304 Cholesterol is an essential structural component of the cell membrane, which is necessary for the body to function^{1,2}. However, the risk of CVD is associated with a high level of cholesterol 305 that can be determined by genetic risk factors^{4, 46, 47}. Although the genetic study of cholesterol 306 307 has been conducted, it is not clear how genetic effects on cholesterol vary across different 308 ancestries. In this study, we explicitly estimated cross-ancestry genetic correlations to 309 investigate the shared genetic architecture across ancestries for cholesterol. Importantly, we 310 appropriately accounted for the relationship between allele frequency and per-allele effect size 311 by modelling the ancestry-specific scale factor for cholesterol, which can provide more reliable estimates³¹. 312

313

314 The reliable estimation of cross-ancestry genetic correlation allows us to understand the shared 315 genetic architecture across ancestries, providing crucial information when for various 316 downstream analyses of complex traits such as cross-ancestry GWAS and cross-ancestry 317 polygenic risk score prediction. Moreover, this may inform best practices for cross-ancestry 318 meta-analysis, multi-ancestry disease mapping, and the transferability of epidemiological 319 findings. Our analysis shows that in general, total- and LDL-cholesterol are both genetically heterogeneous across ancestries, whereas HDL-cholesterol is not⁴⁸. This finding has important 320 321 implications for the power of cross-ancestry GWASs and cross-ancestry polygenic risk score 322 prediction, which for HDL-cholesterol may be much higher than that for total- and LDL-323 cholesterols (Supplementary Figure 6).

324

To identify genetic variants that contribute to the genetic heterogeneity, we investigated concordant and discordant SNP sets that were identified by comparing the direction of SNP effects between UK Biobank and Biobank Japan GWAS summary statistics, noting that the two datasets are independent from the four target ancestry groups used in this study. The concordant SNPs may be associated with genes that are functionally homogeneous across ancestries⁴⁹, and we show in this study that the concordant SNPs are more often located in the

regulatory or genic regions, compared to other genomic regions. We also show that such strong genetic heterogeneity across ancestries for cholesterol can be attributed to the discordant SNPs, but not to the concordant SNPs. We provide evidence that the set of concordant SNPs can be useful in the cross-ancestry polygenic risk predictions, which may improve the transferability of polygenic risk scores to clinical practice^{16, 50, 51}.

336

337 There are a number of limitations in this study. For determining optimal α , we did not consider the relationship between LD and per-allele effect sizes, i.e., as in LDAK-thin model³² that 338 requires a substantial reduction of the number of SNPs. We also acknowledge that the 339 340 conclusions from cross-ancestry analyses (cross-ancestry correlation and genomic prediction) 341 in this study are restricted to common variants (MAF ≥ 0.01) and HapMap3 SNPs only; as these are robust and reliable for dissecting cross-ancestry genetic architecture^{52, 53}. A moderate 342 343 sample size (limited power of the data) was used to estimate optimal scale factors (α) for south Asian and African populations. Therefore, the genetic heterogeneity needs to be explored with 344 345 larger sample size. The concordant SNPs were identified by comparing the direction of SNP 346 effects between white British (UKBB) and East Asian (BBJ) populations, because adequate 347 data was not available from other ancestries. When public genomic databases have sufficient 348 resources across ancestries, we can have a finer set of concordant SNPs by comparing SNP 349 effects across various ancestries.

350

351 In conclusion, there is a significant genetic heterogeneity between ancestries for total- and 352 LDL-cholesterol, which is mostly driven by the set of discordant SNPs. Interestingly, the 353 concordant SNPs are more frequently found in the regulatory region as annotated by an 354 independent study⁵⁴, and restricting to concordant SNPs can provide better accuracy for cross-355 ancestry polygenic prediction for cholesterol. Our findings contribute to knowledge about the 356 genetic architecture of cholesterol that is shared across ancestries. The proposed cross-ancestry 357 polygenic prediction can be potentially useful in clinical practice. Our analysis protocol can be extended to a wide range of other complex traits and diseases. 358

359

- 360
- 361 Methods

362 **Ethical statement**

We used publicly available from the UK Biobank (<u>https://www.ukbiobank.ac.uk/</u>). Science protocol and operational procedures for the UK Biobank have been reviewed and approved by

365 the North-West Multi-Centre Research Ethics Committee (MREC), National Information Governance Board for Health & Social Care (NIGB), and Community Health Index Advisory 366 367 Group (CHIAG). The UK Biobank has obtained consent from all participants. The access of 368 the UK Biobank data was approved under the reference number 14575 ("Whole genome 369 approaches for dissecting (shared) genetic architecture and individual risk prediction of 370 complex traits in human populations"). Publicly available GWAS summary statistics of 371 Biobank Japan (BBJ) were used, following BBJ's guidelines (http://jenger.riken.jp/en/). The 372 research ethics approval of this study has been obtained from the University of South Australia 373 Human Research Ethics Committee.

- 374
- 375

376 **Participants and stratification of ancestries**

Data from the UK Biobank contains 501,748 participants recruited between 2006 and 2010⁵⁵. The participants were recruited from 22 assessment centres in England, Wales, and Scotland, ranging in age from 37 to 73 years old⁵⁶. All the phenotypic data for cholesterol traits under this study are derived from baseline survey. Principal component analysis was applied to the UK Biobank individuals to stratify participants⁵⁷ into four different ancestries following previous approach³¹.

- 383
- 384

385 Genotypic data and quality control

386 We used the second release of the UK biobank (https://www.ukbiobank.ac.uk/) genotype data 387 comprising 488,377 individuals and 92,693,895 imputed autosomal SNPs. The individuals 388 were genotyped by Affymetrix UK BiLEVE Axiom array and Affymetrix UK Biobank 389 Axiom® array. Combination of UK10K and Haplotype Reference Consortium (HRC) data 390 were considered as the reference dataset for the imputation of the UK Biobank genotypic 391 dataset⁵⁸. In this analysis, to dissect the genetic architecture of disease and complex traits, we retained only HapMap3 SNPs in this analysis⁵², which are also considered robust and reliable 392 for estimating heritability, genetic correlation^{52, 59}. Stringent quality control (QC) procedure 393 394 was applied to each ancestry to select high quality individuals and high-quality SNPs. SNPs 395 QC criteria include, SNPs excluded with an INFO score (used to indicate the quality of genotype imputation) $<0.6^{60-62}$, call rate <0.95, a MAF <0.01 and a Hardy–Weinberg 396 equilibrium *p*-value $<10^{-4}$. We also exclude population outliers (individuals outside ± 6 SD) and 397 related individuals (--rel-cutoff 0.05) using PLINK⁶³. 398

399

400 Individual level QC criteria include samples with genotype missing rate >0.05, gender 401 mismatch (reported gender does not fit with the genetically assigned sex determined from gene 402 data), poor genotype quality or a sex chromosome aneuploidy was excluded from the main 403 analyses. For the ease of computation, we reduced the number individuals in white British 404 ancestry. The total number of individuals and total number of SNPs after QC shown in 405 Supplementary Table 1. The number of common SNPs across different pairs of ancestries presented in Supplementary Table 2 and the number of common SNP for each genomic 406 407 region (genomic partitioning) between ancestries presented in Supplementary Table 3.

408

409 Functional annotation of the genome

410 The common SNPs between populations were partitioned into genomic region using genomic annotation reported by Gusev et. al.⁵⁴, where they partitioned the genome into coding, UTR, 411 promoter, intron, DHS and intergenic regions. For the genomic partitioning analysis, we 412 include promoter, coding, UTR, and DHS regions as regulatory regions⁶⁴⁻⁶⁶, and introns (an 413 integral part of a gene)^{67, 68} and the intergenic regions as non-genic regions. We also partitioned 414 415 the whole genome into two predefined functional categories as genic (includes SNPs from 416 promoter, coding, untranslated, intron and DHS region) and non-genic regions (intergenic 417 region).

418

419 **Concordant and discordant SNP annotation**

420 To identify concordant and discordant SNPs we compared SNP effects between two 421 independent GWAS datasets of white British from UK Biobank and Biobank Japan (BBJ). The 422 BBJ summary statistics data are publicly available (http://jenger.riken.jp/en/result). We 423 excluded SNPs that were ambiguous or had a strand issue. After excluding these SNPs, there 424 were 4,113,630 SNPs that are common between UKBB and BBJ. To determine concordant and 425 discordant SNPs, we compared the direction of SNP effects between white British from UKBB and BBJ. We used only HapMap3 SNPs from 4,113,630 SNPs for concordant and discordant 426 427 analysis across different ancestry pairs (Supplementary Table 4).

- 428
- 429 There were four possible combinations of direction of SNP effects (beta):
- 430 (+beta, +beta) if the SNP effects are positive in both GWAS.
- 431 (+beta, -beta) if the SNP effects are positive and negative in the UKBB and BBJ GWAS.
- (-beta, +beta) if the SNP effects are negative and positive in the UKBB and BBJ GWAS. 432

433 (-beta, -beta) if the SNP effects are negative in both GWAS.

- 434 Each SNP should be in one of four possible combinations and belongs to either concordance
- 435 or discordance. SNPs belonged to ((+beta, +beta) U (-beta, -beta) were considered concordant,
- 436 otherwise discordant, i.e. (+beta, -beta) U (-beta, +beta).
- 437
- 438

439 Data analysis

440 **Phenotypic adjustment of main traits**

Prior to model fitting, all cholesterol traits were adjusted for demographic variables, the UK biobank assessment centre (as factor), genotype measurement batch (as factor) and population structure measured by the first 10 principal components (PCs)^{64, 69} using linear models in *R-software* (4.0.3). Demographic variable includes sex, birth year, education, and Townsend deprivation index (**Supplementary Table 5**). Information of educational qualifications converted to education levels (years) for all the UK Biobank individuals⁷⁰.

447

448 **Determining scale factors for GCTA-***α* **model**

- 449 GCTA model assumes all the SNPs has equal contribution to the genetic variance (has no LD 450 weights), whereas LDAK-thin model³² explicitly considers LD among SNPs. The previously recommended and widely used α are -0.50 and -0.125 for GCTA model⁷¹ and LDAK-thin 451 452 model³², respectively. Here we have used 13 different values of α (between -1 and 0.5) following GCTA model (termed as GCTA- α model)³¹. In order to perform a cross-ancestry 453 genetic correlation analysis of cholesterol traits (total cholesterol, HDL cholesterol, and LDL 454 455 cholesterol), we determined and used optimal α based on GCTA models for each trait and 456 ancestry. We did not consider another widely used LDAK-thin model as it will reduce number 457 of common SNPs between ancestry due to LD-pruning.
- 458

459 Statistical models

460 Univariate Linear Mixed Model

461 The univariate Linear Mixed Model (LMM) for can be written as,

$462 \quad \mathbf{y} = \mathbf{X}\mathbf{b} + \mathbf{Z}\mathbf{g} + \mathbf{e}$

(1)

- Where **y** is the vector of phenotypic observation, **b** is the vector of fixed effects, **g** is the vector of additive genetic value and **e** is the vector of the residuals. The random effects (**g** and **e** are
- 465 presumed to be distributed normally with mean zero where **X** and **Z** are incidence matrices

466

467 Heritability was estimated using the genetic and residual variances obtained from the univariate

468 LMM, which can be expressed as

$$h^2 = \frac{\sigma_g^2}{\sigma_g^2 + \sigma_e^2} \tag{2}$$

for ancestry 2(4)

469 Here, σ_{g}^{2} is the genetic variance and σ_{e}^{2} is residual variance. Estimation assumed 470 environmental homogeneity

471

472 Bivariate Linear Mixed Model

The bivariate Linear Mixed Model (LMM) was used to estimate heritability and cross-ancestry
genetic correlation using individual level genetic data written as,

475
$$y_1 = X_1 b_1 + Z_1 g_1 + e_1$$
 for ancestry 1 (3)

$$476 \quad \mathbf{y}_2 = \mathbf{X}_2 \mathbf{b}_2 + \mathbf{Z}_2 \mathbf{g}_2 + \mathbf{e}_2$$

Where y_1 and y_2 are vector of phenotypic observation, $\mathbf{b_1}$ and $\mathbf{b_2}$ are the vector of fixed effects, $\mathbf{g_1}$ and $\mathbf{g_2}$ are vector of additive genetic value and $\mathbf{e_1}$ and $\mathbf{e_2}$ are the vector of residuals. The random effects ($\mathbf{g_1}, \mathbf{g_2}$ and $\mathbf{e_1}, \mathbf{e_2}$) are presumed to be distributed normally with mean zero where X and Z are incidence matrices i.e. i.e. $\mathbf{g_i} \sim N(0, A\sigma_{gl}^2)$ and $\mathbf{e_i} \sim N(0, I\sigma_{el}^2)$. 481

482 The variance covariance matrix of observed phenotypes can be written as

483
$$\mathbf{V} = \begin{bmatrix} \mathbf{Z}_1 \mathbf{A} \sigma_{g_1}^2 \mathbf{Z}'_1 + \mathbf{I} \sigma_{e_1}^2 & \mathbf{Z}_1 \mathbf{A} \sigma_{g_{12}}^2 \mathbf{Z}'_2 \\ \mathbf{Z}_2 \mathbf{A} \sigma_{g_{21}}^2 \mathbf{Z}'_1 & \mathbf{Z}_2 \mathbf{A} \sigma_{g_2}^2 \mathbf{Z}'_2 + \mathbf{I} \sigma_{e_2}^2 \end{bmatrix}$$
(5)

where, **A** is the genomic relationship matrix $(GRM)^{72-74}$, which can be estimated based on the 484 genome-wide SNP information, and I is an identity matrix which implicitly assumes across 485 individuals of environmental effects and measurement error. The terms, $\sigma_{g_1}^2(\sigma_{g_2}^2)$ and 486 $\sigma_{e_1}^2(\sigma_{e_2}^2)$ indicate the genetic and residual variance of the trait for the two-ancestry group, and 487 $\sigma_{g_{12}}^2(\sigma_{g_{21}}^2)$ is the genetic covariances between the two ancestry groups. It is noted that there is 488 489 no parameter to model residual correlation in V because there are no multiple phenotypic 490 measures for any individual, i.e., the phenotypes of the first (second) trait are available only 491 for the first (second) ancestry group.

492

493 Cross-ancestry genetic correlation between two random genetic effects can be computed either 494 directly as genetic covariance standardized by the square root of the product of the genetic

495 variances of the two random genetic effects (equation 6) or indirectly by the correlation 496 coefficient of SNP effect sizes^{38, 75}.

$$r_{\mathbf{g}_{i}\mathbf{g}_{j}} = \frac{\sigma_{\mathbf{g}_{i}\mathbf{g}_{j}}}{\sqrt{\sigma_{\mathbf{g}_{i}}^{2} \cdot \sigma_{\mathbf{g}_{j}}^{2}}} \tag{6}$$

497

498 **GREML** analysis to estimate heritability and cross-ancestry genetic correlations

Bivariate GREML is the cornerstone method to estimate SNP heritability and cross-ancestry genetic correlation using common SNPs across ancestries. The SNPs frequency, heritability model (relationship between heritability and MAF), and the scale factor (α) varied across ancestries³¹. We used a recently proposed approach of estimating GRM³¹ in combined population, that accounts ancestry specific α and ancestry specific allele frequencies for estimating heritability and cross-ancestry genetic correlation. Both estimation of GRM and GREML analysis was implemented in $mtg2^{76}$.

506

507 Genomic prediction

508 The polygenic score (PGS) is obtained from by aggregating and quantifying single nucleotide 509 polymorphism (SNP) effects. PGS of an individual (*k*) can be defined as cumulative effect of 510 SNP counts with a standard equation as:

- 511 $PGS = \sum_{j=1}^{m} \beta_j x_{jk}$
- 512 Here, β_j is the SNP effect from discovery GWAS, *m* is the total number of SNPs included in 513 the predictor, x_{jk} is the number of copies (0,1, or 2) of trait associated SNP *j* in the genotype 514 of individual *k*.
- 515
- 516

517 Web resources and code availability

The genotype and phenotype data of the UK Biobank can be accessed through procedures described on its webpage (<u>https://www.ukbiobank.ac.uk/</u>) and summary statistics of BMI and

520 total-, LDL- and HDL-cholesterol from Biobank Japan (BBJ) can be obtained from its website

521 (http://jenger.riken.jp/en/result)

- 522 MTG2, <u>https://sites.google.com/site/honglee0707/mtg2</u>
- 523 PLINK2 version can be downloaded from <u>https://www.cog-genomics.org/plink/</u>
- 524 *r2redux* R-package (<u>https://github.com/mommy003/r2redux</u> from GitHub or from CRAN)

- 525 The GWAS summary statistics dataset that is generated in this current study and supports the
- 526 findings have been deposited in the NHGRI-EBI GWAS catalogue with the accession codes
- 527 GCST90244051, GCST90244052, GCST90244053, GCST90244054, GCST90244055 and
- 528 GCST90244056; (https://www.ebi.ac.uk/gwas/). GWAS for all SNPs and concordant SNPs for
- 529 total-, HDL- and LDL-cholesterol can be accessed in following links
- 530 GWAS of total cholesterol (all SNP)
- 531 (https://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST90244001-
- GCST90245000/GCST90244051/) 532
- 533 GWAS of total cholesterol (concordant SNP)
- 534 (https://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST90244001-
- 535 GCST90245000/GCST90244052/)
- 536 GWAS of HDL-cholesterol (all SNP)
- 537 (https://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST90244001-
- GCST90245000/GCST90244053/) 538
- 539 GWAS for HDL-cholesterol (concordant SNP)
- 540 (https://ftp.ebi.ac.uk/pub/databases/gwas/summary statistics/GCST90244001-
- GCST90245000/GCST90244054/) 541
- 542 GWAS for LDL-cholesterol (all SNP)
- (https://ftp.ebi.ac.uk/pub/databases/gwas/summary statistics/GCST90244001-543
- 544 GCST90245000/GCST90244055/)
- 545 GWAS for LDL-cholesterol (concordant SNP)
- 546 (https://ftp.ebi.ac.uk/pub/databases/gwas/summary_statistics/GCST90244001-
- 547 GCST90245000/GCST90244056/)
- 548
- 549

550 Acknowledgements

- 551 This research is supported by the Australian Research Council (DP190100766). We thank the
- 552 staff and participants of the UK Biobank and Biobank Japan for their important contributions.
- 553 Our reference number approved by UK Biobank is 14575. The analyses were performed using
- 554 computational resources provided by the Australian Government through Gadi under the
- 555 National Computational Merit Allocation Scheme (NCMAS), and HPCs (Statgen server)
- 556 managed by UniSA IT.
- 557

558 **Declaration of interest**

- 559 The authors declare that they do not have any competing interests.
- 560
- 561
- 562
- 563
- 564 **References**

565	1.	Ding, X., et al., The role of cholesterol metabolism in cancer. American journal of cancer
566		research, 2019. 9 (2): p. 219.
567	2.	Yan, S., et al., Bufalin enhances TRAIL-induced apoptosis by redistributing death receptors in
568		lipid rafts in breast cancer cells. Anti-cancer drugs, 2014. 25 (6): p. 683-689.
569	3.	Craig, M., S.N.S. Yarrarapu, and M. Dimri, <i>Biochemistry, cholesterol.</i> 2018.
570	4.	Musunuru, K. and S. Kathiresan, <i>Genetics of common, complex coronary artery disease</i> , Cell.
571		2019 177 (1): n. 132-145
572	5	WHO World Health Organization: Cardiovascular diseases (CVDs) 2021
573	6	Trinder M G A Francis and I B Brunham Association of monogenic vs polygenic
574	0.	hypercholesterolemia with risk of atherosclerotic cardiovascular disease IAMA cardiology
575		$2020 \ 5(4) \cdot \mathbf{n} \ 390-399$
576	7	Verbeek P et al. Cardiovascular disease risk associated with elevated linoprotein (a)
570	7.	attenuates at low low density linearetain shalestared loyals in a primary provention setting
570		European beart journal 2018 20 (27) n 2590 2506
570	0	European neart journal, 2018. 39 (27): p. 2589-2596.
519	8.	Go, A.S., et al., Heart disease and stroke statistics—2013 update: a report from the American
58U	0	Heart Association. Circulation, 2013. 127 (1): p. e6-e245.
581	9.	Andaleon, A., L.S. Mogil, and H.E. Wheeler, Gene-based association study for lipid traits in
582		diverse cohorts implicates BACE1 and SIDT2 regulation in triglyceride levels. PearJ 2018. 6: p.
583		e4314.
584	10.	Trinder, M., et al., Polygenic contribution to low-density lipoprotein cholesterol levels and
585		cardiovascular risk in monogenic familial hypercholesterolemia. Circulation: Genomic
586		Precision Medicine, 2020. 13 (5): p. 515-523.
587	11.	Motazacker, M.M., et al., Evidence of a polygenic origin of extreme high-density lipoprotein
588		cholesterol levels. Arteriosclerosis, Thrombosis and Vascular biology, 2013. 33(7): p. 1521-
589		1528.
590	12.	Weiss, L.A., et al., The sex-specific genetic architecture of quantitative traits in humans. Nature
591		genetics, 2006. 38 (2): p. 218-222.
592	13.	Ma, L., et al., Genome-wide association analysis of total cholesterol and high-density
593		lipoprotein cholesterol levels using the Framingham heart study data. BMJ medical genetics,
594		2010. 11 (1): p. 1-11.
595	14.	Klarin, D., et al., Genetics of blood lipids among~ 300,000 multi-ethnic participants of the
596		Million Veteran Program. Nature Genetics, 2018. 50(11): p. 1514-1523.
597	15.	Liu, D.J., et al., Exome-wide association study of plasma lipids in> 300,000 individuals. Nature
598		genetics, 2017. 49 (12): p. 1758-1766.
599	16.	Martin, A.R., et al., Clinical use of current polygenic risk scores may exacerbate health
600		<i>disparities</i> . Nature Genetics, 2019. 51 (4): p. 584-591.
601	17.	Bustamante, C.D. and E.G. Burchard, <i>De la Vega FM. Genomics for the world</i> . Nature, 2011.
602		475 (7355): p. 163-5.
603	18.	Oh, S.S., et al., Making precision medicine socially precise. Take a deep breath. American
604	-	Journal of Respiratory and Critical Care Medicine, 2016.
605	19	Duncan L. et al. Analysis of polygenic risk score usage and performance in diverse human
606	10.	nonulations Nature Communications 2019 10 (1): n 1-9
607	20	Morris A P Transethnic meta-analysis of genomewide association studies Genetic
608	20.	Enidemiology 2011 35 (8): p. 809-822
609	21	Okada V et al Genetics of rheumatoid arthritis contributes to hiology and drug discovery
610	21.	Nature 2014 506/7488): n 376-381
611	22	Brown BC et al Transethnic genetic-correlation estimates from summary statistics. The
612	<i></i> .	American Journal of Human Genetics 2016 99 (1): n 76-88
613	23	Galinsky KI at al Estimating cross-nonulation genetic correlations of causal effect sizes
614	23.	Genetic Enidemiology 2019 43 (2): n 180-188
UIT		Generic Lpidennology, 2013. 49(2). p. 100-100.

medRxiv preprint doi: https://doi.org/10.1101/2023.01.31.23285307; this version posted February 2, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

- 615 24. Veturi, Y., et al., Modeling heterogeneity in the genetic architecture of ethnically diverse 616 groups using random effect interaction models. Genetics, 2019. 211(4): p. 1395-1407.
- 617 25. Takeuchi, F., et al., Interethnic analyses of blood pressure loci in populations of East Asian and 618 European descent. Nature Communications, 2018. 9(1): p. 1-16.
- 619 Rosenberg, N.A., et al., Genome-wide association studies in diverse populations. Nature 26. Reviews Genetics, 2010. 11(5): p. 356-366. 620
- 621 27. McClellan, J. and M.-C. King, Genetic heterogeneity in human disease. Cell, 2010. 141(2): p. 622 210-217.
- 623 Benyamin, B., et al., Cross-ethnic meta-analysis identifies association of the GPX3-TNIP1 locus 28. 624 with amyotrophic lateral sclerosis. Nature Communications, 2017. 8(1): p. 1-7.
- 625 29. Ding, K. and I.J. Kullo, Evolutionary genetics of coronary heart disease. Circulation, 2009. 626 **119**(3): p. 459-467.
- 627 Shi, H., et al., Population-specific causal disease effect sizes in functionally important regions 30. 628 *impacted by selection.* Nature communications, 2021. **12**(1): p. 1-15.
- 629 31. Momin, M.M., et al., A novel method for an unbiased estimate of cross-ancestry genetic 630 correlation using individual-level data. bioRxiv, 2021.
- 631 Speed, D., et al., Reevaluation of SNP heritability in complex human traits. Nature Genetics, 32. 632 2017. 49(7): p. 986-992.
- 633 33. Martin, A.R., et al., Human demographic history impacts genetic risk prediction across diverse 634 populations. The American Journal of Human Genetics, 2017. 100(4): p. 635-649.
- 635 34. Márquez-Luna, C., et al., Multiethnic polygenic risk scores improve risk prediction in diverse 636 populations. Genetic Epidemiology, 2017. 41(8): p. 811-823.
- 637 35. Vilhjálmsson, B.J., et al., Modeling linkage disequilibrium increases accuracy of polygenic risk 638 scores. The American Journal of Human Genetics, 2015. 97(4): p. 576-592.
- 639 Lam, M., et al., Comparative genetic architectures of schizophrenia in East Asian and European 36. 640 populations. Nature Genetics, 2019. 51(12): p. 1670-1678.
- 641 37. Neshat, M., et al., A novel hyper-parameter can increase the prediction accuracy in a single-642 step genetic evaluation. BioRxiv, 2022: p. 2022.07.03.498620.
- 643 38. Lee, S.H., et al., Estimation of pleiotropy between complex diseases using single-nucleotide 644 polymorphism-derived genomic relationships and restricted maximum likelihood. 645 Bioinformatics, 2012. 28(19): p. 2540-2542.
- 646 Speed, D., et al., Improved heritability estimation from genome-wide SNPs. The American 39. 647 Journal of Human Genetics, 2012. 91(6): p. 1011-1021.
- 648 40. Speed, D., J. Holmes, and D.J. Balding, Evaluating and improving heritability models using 649 summary statistics. Nature Genetics, 2020. 52(4): p. 458-462.
- 650 41. lliadou, A., et al., Heritabilities of lipids in young European American and African American 651 twins. Twin Research and Human Genetics, 2005. 8(5): p. 492-498.
- 652 42. Peterson, R.E., et al., Genome-wide association studies in ancestrally diverse populations: 653 opportunities, methods, pitfalls, and recommendations. Cell, 2019. 179(3): p. 589-603.
- 654 43. Marigorta, U.M. and A. Navarro, High trans-ethnic replicability of GWAS results implies 655 common causal variants. PLoS Genet, 2013. 9(6): p. e1003566.
- 656 44. Euesden, J., C.M. Lewis, and P.F. O'Reilly, PRSice: polygenic risk score software. Bioinformatics, 657 2015. **31**(9): p. 1466-1468.
- 658 45. Momin, M.M., et al., Significance tests for R2 of out-of-sample prediction using polygenic 659 scores. The American Journal of Human Genetics, 2023.
- 660 46. Nelson, R.H., Hyperlipidemia as a risk factor for cardiovascular disease. Primary Care: Clinics 661 in Office Practice, 2013. 40(1): p. 195-211.
- 662 Tall, A.R., et al., Addressing dyslipidemic risk beyond LDL-cholesterol. The Journal of Clinical 47. 663 Investigation, 2022. **132**(1).
- 664 48. Kuchenbaecker, K., et al., The transferability of lipid loci across African, Asian and European 665 cohorts. Nature Communications, 2019. 10(1): p. 1-10.

medRxiv preprint doi: https://doi.org/10.1101/2023.01.31.23285307; this version posted February 2, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

- 666 49. Cao, C., Analysis of Concordance and Discordance in Genetic Association Studies via Forward-667 Backward Scoring Scheme, Masters Thesis. 2020, The Ohio State University.
- 668 Huang, Q.Q., et al., Transferability of genetic loci and polygenic scores for cardiometabolic 50. traits in British Pakistani and Bangladeshi individuals. Nature communications, 2022. 13(1): p. 669 670 1-11.
- 671 51. Lewis, C.M. and E. Vassos, Polygenic risk scores: from research tools to clinical instruments. 672 Genomic Medicine, 2020. 12: p. 1-11.
- 673 52. Tropf, F.C., et al., Hidden heritability due to heterogeneity across seven populations. Nature 674 Human Behaviour, 2017. 1(10): p. 757-765.
- 675 53. Bulik-Sullivan, B., et al., ReproGen Consortium Psychiatric Genomics Consortium Genetic 676 Consortium for Anorexia Nervosa of the Wellcome Trust Case Control Consortium 3 An atlas of 677 genetic correlations across human diseases and traits. Nat Genet, 2015. 47(11): p. 1236-1241.
- 678 Gusev, A., et al., Partitioning heritability of regulatory and cell-type-specific variants across 11 54. 679 common diseases. The American Journal of Human Genetics, 2014. 95(5): p. 535-552.
- 680 55. Fry, A., et al., Comparison of sociodemographic and health-related characteristics of UK 681 Biobank participants with those of the general population. American Journal of Epidemiology, 682 2017. 186(9): p. 1026-1034.
- 683 56. Ollier, W., T. Sprosen, and T. Peakman, UK Biobank: from concept to reality. Future Medicine, 684 2005.
- 685 Novembre, J. and M. Stephens, Interpreting principal component analyses of spatial 57. 686 population genetic variation. Nature Genetics, 2008. 40(5): p. 646-649.
- 687 58. Loh, P.-R., et al., Reference-based phasing using the Haplotype Reference Consortium panel. 688 Nature Genetics, 2016. 48(11): p. 1443.
- 689 59. Bulik-Sullivan, B., et al., ReproGen Consortium Psychiatric Genomics Consortium Genetic 690 Consortium for Anorexia Nervosa of the Wellcome Trust Case Control Consortium 3 An atlas of 691 genetic correlations across human diseases and traits. Nature Genetics, 2015. 47(11): p. 1236-692 1241.
- 693 60. Border, R., et al., Imputation of behavioral candidate gene repeat variants in 486,551 publicly-694 available UK Biobank individuals. European Journal of Human Genetics, 2019. 27(6): p. 963-695 969.
- 696 Lee, S.H., W.S.P. Weerasinghe, and J.H. Van Der Werf, Genotype-environment interaction on 61. 697 human cognitive function conditioned on the status of breastfeeding and maternal smoking 698 around birth. Scientific Reports, 2017. 7(1): p. 1-12.
- 699 62. Peyrot, W.J., et al., Does childhood trauma moderate polygenic risk for depression? A meta-700 analysis of 5765 subjects from the psychiatric genomics consortium. Biological Psychiatry, 701 2018. **84**(2): p. 138-147.
- 702 63. Purcell, S., et al., PLINK: a tool set for whole-genome association and population-based linkage 703 analyses. The American Journal of Human Genetics, 2007. 81(3): p. 559-575.
- 704 64. Zhou, X., H.K. Im, and S.H. Lee, CORE GREML for estimating covariance between random 705 effects in linear mixed models for complex trait analyses. Nature Communications, 2020. 706 **11**(1): p. 1-11.
- 707 65. Ni, G., et al., Estimation of genetic correlation via linkage disequilibrium score regression and 708 genomic restricted maximum likelihood. The American Journal of Human Genetics, 2018. 709 **102**(6): p. 1185-1194.
- 710 66. Meuleman, W., et al., Index and biological spectrum of human DNase I hypersensitive sites. 711 Nature 2020. 584(7820): p. 244-251.
- 712 67. Yadav, M.L. and B. Mohapatra, Intergenic regions, also known as spacer DNA. 2018.
- 713 Gilbert, W., Genes-in-pieces revisited. Science, 1985. 228: p. 823-825. 68.
- 714 69. Jin, J., et al. Principal components ancestry adjustment for Genetic Analysis Workshop 17 data. 715 in BMC Proceedings. 2011. BioMed Central.

- 716 70. Okbay, A., et al., *Genome-wide association study identifies 74 loci associated with educational* 717 *attainment.* Nature, 2016. 533(7604): p. 539-542.
- 71. Yang, J., et al., *GCTA: a tool for genome-wide complex trait analysis.* The American Journal of
 719 Human Genetics, 2011. 88(1): p. 76-82.
- 720 72. VanRaden, P.M., *Efficient methods to compute genomic predictions.* Journal of Dairy Science,
 721 2008. **91**(11): p. 4414-4423.
- 722 73. Yang, J., et al., *Common SNPs explain a large proportion of the heritability for human height*.
 723 Nature Genetics, 2010. 42(7): p. 565-569.
- 72474.Amin, N., C.M. Van Duijn, and Y.S. Aulchenko, A genomic background based method for725association analysis in related individuals. PloS One, 2007. 2(12): p. e1274.
- 72675.Bulik-Sullivan, B.K., et al., LD Score regression distinguishes confounding from polygenicity in727genome-wide association studies. Nature genetics, 2015. 47(3): p. 291.
- 72876.Lee, S.H. and J.H. Van der Werf, *MTG2: an efficient algorithm for multivariate linear mixed*729model analysis based on genomic information. Bioinformatics, 2016. **32**(9): p. 1420-1422.

730